(ARS Pharma). The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers ...

(“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan ...

("ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China.

Exclusive rights to new indications ARS Pharma is also developing its intranasal adrenaline (epinephrine) technology for the treatment of acute flares in patients with chronic urticaria ...

A nasal spray developed to treat life-threatening ... at risk of potentially fatal anaphylaxis to inject themselves with ...

Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxis ALK also gains rights to future indications, including acute urticaria flares (in ...

Exclusive rights to new indications ARS Pharma is also developing its intranasal adrenaline (epinephrine) technology for the treatment of acute flares in patients with chronic urticaria, with plans to ...

(“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China.